Company Encyclopedia
View More
name
KMYY
600518.SH
Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese herbal medicines in China. The company offers Chinese patent medicines, chemical medicines, and health food products. In addition, it engages in the operation of Chinese medicinal materials markets; production and sale of medical devices; and operation of pharmaceutical logistics system.
3.157 T
600518.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking83/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE0.23%D
    • Profit Margin0.32%C
    • Gross Margin19.55%D
  • Growth ScoreD
    • Revenue YoY1.18%C
    • Net Profit YoY-93.49%E
    • Total Assets YoY-3.60%D
    • Net Assets YoY2.10%C
  • Cash ScoreB
    • Cash Flow Margin31700.97%A
    • OCF YoY1.18%C
  • Operating ScoreC
    • Turnover0.38C
  • Debt ScoreC
    • Gearing Ratio47.20%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    KMYY released its performance for the first three quarters, with a net profit attributable to the parent company of 13.08 million yuan, a year-on-year increase of 160.84%

    According to the Zhitong Finance APP, KMYY disclosed its third-quarter report for 2025, stating that the company achieved revenue of 3.96 billion yuan in the first three quarters, a year-on-year increase of 2.22%; net profit attributable to the parent company was 13.08 million yuan, a year-on-year increase of 160.84%; the net profit excluding non-recurring gains and losses was a loss of 37.94 million yuan; basic earnings per share were 0.001 yuan

    Zhitong·
    SH
    600518
    0.00%
    Zhitong·
    SH
    600518
    0.00%

    KMYY released its semi-annual performance, with a net profit attributable to the parent company of 16.9 million yuan, a year-on-year increase of 7.24%

    According to the Zhitong Finance APP, KMYY disclosed its semi-annual report for 2025, stating that the company achieved revenue of 2.577 billion yuan during the reporting period, a year-on-year increase of 4.17%; net profit attributable to the parent company was 16.9 million yuan, a year-on-year increase of 7.24%; the net profit excluding non-recurring items was a loss of 3.62 million yuan; basic earnings per share were 0.001 yuan

    Zhitong·
    SH
    600518
    0.00%
    Zhitong·
    SH
    600518
    0.00%

    KMYY: Plans to sign a settlement agreement with related party Guangzhou Pharmaceutical Group to resolve historical debt issues for 43.5 million yuan

    KMYY announced that its wholly-owned subsidiary Chengdu KMYY Pharmaceutical Co., Ltd. intends to sign a settlement agreement with Guangzhou Pharmaceutical Group Co., Ltd. to settle the aforementioned debt with 43.5 million yuan and related handling fees. After the payment is completed, the Guangzhou Pharmaceutical Group will assist Chengdu KMYY in handling the execution unsealing and case closure procedures. This transaction constitutes a related party transaction but does not constitute a major asset reorganization

    Zhitong·
    SH
    600518
    0.00%
    Zhitong·
    SH
    600518
    0.00%

    KMYY: The current ginseng planting area is 14,700 acres

    On the afternoon of May 23, Ou Guoxiong, director and general manager of KMYY, responded to the ginseng planting situation at the 2024 annual performance briefing, stating that as of December 31, 2024, the company's subsidiary Jianshan Dadi Ginseng Industry Co., Ltd. has accumulated a total of 51,200 acres of land in circulation, with a cumulative fresh ginseng harvesting area of 36,500 acres, a current ginseng planting area of 14,700 acres, and an additional 2,000 acres of land available for planting. The ginseng planting and harvesting work is progressing smoothly

    Zhitong·
    SH
    600518
    0.00%
    Zhitong·
    SH
    600518
    0.00%

    KMYY released its 2024 annual performance, with a net profit attributable to shareholders of RMB 8.5737 million, a year-on-year decrease of 91.64%

    According to the Zhitong Finance APP, KMYY released its 2024 annual report, stating that the company's operating revenue for 2024 was 5.189 billion yuan, a year-on-year increase of 6.47%; the net profit attributable to shareholders of the listed company was 8.5737 million yuan, a year-on-year decrease of 91.64%; the net loss attributable to shareholders of the listed company, after deducting non-recurring gains and losses, was 533 million yuan, with losses narrowing; the basic earnings per share were 0.0006 yuan/share

    Zhitong·
    SH
    600518
    0.00%
    Zhitong·
    SH
    600518
    0.00%
    © 2025 Longbridge｜Disclaimer